Skip to main content

Research Repository

Advanced Search

Outputs (577)

Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review (2022)
Journal Article

Background: The benefit of chemotherapy for older patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) is a key area of debate. Gene expression profiling (GEP) may identify p... Read More about Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review.

NIHR Nottingham Biomedical Research Centre (BRC) Musculoskeletal theme: virtual conference proceedings 24 th & 25 th February 2022 (2022)
Working Paper

This paper gives summaries of the keynote lectures given and the research abstracts presented at the NIHR Nottingham Biomedical Research Centre Musculoskeletal theme virtual conference held on 24th and 25th February 2022. The purpose of the confere... Read More about NIHR Nottingham Biomedical Research Centre (BRC) Musculoskeletal theme: virtual conference proceedings 24 th & 25 th February 2022.

Availability of active therapeutic hypothermia at birth for neonatal hypoxic ischaemic encephalopathy: a UK population study from 2011 to 2018 (2022)
Journal Article

Objective: Therapeutic hypothermia (TH) commenced soon after birth for neonatal hypoxic ischaemic encephalopathy (HIE) improves survival and reduces neurodisability. Availability of active TH at the place of birth (Immediate-TH) in the UK is unknown.... Read More about Availability of active therapeutic hypothermia at birth for neonatal hypoxic ischaemic encephalopathy: a UK population study from 2011 to 2018.

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists (2022)
Journal Article

The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor ago... Read More about Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.